Gland Surgery

Editor-in-Chief: Xin-sheng Lv, MD

Dr.Prof. Xin-sheng Lv, MD, was born in June 1935. He graduated from the Departmentof Medicine, Hunan Medical College in 1958, and later was trained in CambridgeUniversity and Birmingham University Medical School in 1996 and in YaleUniversity School of Medicine from 1981 to 1983. Dr. Lv currently was aprofessor of surgery and supervisor for doctoral candidates in the Departmentof Surgery of Xiangya Hospital of Central South University. In the XiangyaHospital, he was also the honorary director of the Department of Surgery,director of the Institute of Organ Transplantation, and the deputy head of theExpert Group.

He is the president/editor-in-chief of the Chinese Journal of General Surgeryand the associate editor of the Journal of World Chinese Medicine. Heserved as the standing member or member of over 10 academic journals including ChineseJournal of Experimental Surgery and Chinese Journal of HepatobiliarySurgery.

He was the co-chairman of the "Association of General Surgery in SixProvinces in Central South China", the executive council member of HunanMedical Association, and chairman of Hunan General Surgery Society.

He has published morethan 200 articles in academic journals. He is also the author or co-author ofover 20 books and textbooks in the field of surgery.

Editor-in-Chief: Xi-ru Li, MD

Dr. Prof Xi-ru Li, MD, graduated from the Department of Clinical Medicine of the First Military Medical University in 1989 with a bachelor degree. He worked in the Department of General Surgery, Tang Du Hospital, Fourth Military Medical University, from 1989 to 2000, during which he received his master degree and was trained as attending physician and lecturer. He jointed the Department of General Surgery of PLA General Hospital in September 2000. Currently he acts as the Deputy Executive Director of the Department of General Surgery and also is the chief of the Department of Breast Surgery in PLA General Hospital.

He acts as a consultant for China National Drug and Food Administration new drug evaluation, vice chairman of Military Breast and Endocrine Surgery Society, member of the Military General Surgery Society, member of Chinese Society of Clinical Oncology Breast Cancer Group, and member of Chinese Medical Doctor Association Breast Disease Group. He is the member of the editorial boards of several journals including Chinese Journal of Breast Disease.

He has published 60 plus papers in domestic and international journals. He has obtained a national invention patent. He is the responsible person for the following key research projects: "Application of Proteomics Technology in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer" (MA245), supported by the “11th Five-Year Plan” Military Health Research Fund; "Application of FISH Technology for the Detection of Breast Cancer HER-2 Gene (2007)", supported by the Ministry of Health; "Application of Magnetic Resonance Image Reconstruction and Simulated Surgery in the Breast-conserving Surgery for Patients with Breast Cancer - Breast Precision Surgical Technology" (2010gxjs092), supported by the Military Clinical High-Tech Key Program; and "Application of iTRAQ Proteomics Technology in Analyzing the Changes of the Protein Expressions after Neoadjuvant Chemotherapy for Breast Cancer" (2011), supported by the National Natural Science Fund. Meanwhile, he has participated in many other studies supported by the National "973 Program", "863 Program", and Beijing Municipal Key Program. He has co-authors several books.

He has accumulated rich experiences in medical care, teaching, and relevant research in the past two decades. Under his leadership, a multi-discipline team, known as "Breast Disease Diagnosis and Treatment Cooperative Team of PLA General Hospital" and participated by the department of surgery, department of oncology, department of pathology, department of radiotherapy, department of ultrasound, mammography room, and MRI room, has been established. Doctors who are involved in the management of breast diseases from different departments participate in this team and conduct academic activities regularly. Dr. Li has rich experiences in the early screening, etiological analysis, and clinical treatment of breast tumors. He plays a leading role in the management of clinically non-palpable breast cancer in China and keeps close contact with his international colleagues. He introduced the technique of magnetic resonance (MR)-guided biopsy into China and pioneered the application of intra-operative radiotherapy in the breast-conserving surgery for patients with breast cancer. He is also actively involved in the introduction of sentinel lymph node biopsy, phase I and phase II breast reconstruction after surgery for breast cancer, mastectomy (SSM) with conservation of the nipple-areola complex, implants reconstruction, and Mammotome minimally invasive breast surgery. Furthermore, he has standardized the multi-discipline breast-conserving treatment procedures, established a DNA bank for patients with breast cancer, and conducted pre-clinical and clinical research on pharamcogenomics-guided individualized treatment for breast cancer.